Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Administrators: Do you have an update as to what happened today. I was hyperventilating!!
I may have missed this on a previous posting, but is Covance one of the CRO's?
Interesting to note that the upcoming Immunotherapy World (January 2017) has three forums this time:
1. Immunotherapy World
2. Cell & Gene Therapy World
3. Cord Blood & Tissue
So, here we are:
1. Northwest Biotherapeutics - Linda Powers
2. Cognate BioServices - Linda Powers
3. HealthBank - Linda Powers
Can you say VISIONARY!
Quote:
“What's up with these Poli Science majors opining on bio tech stocks?”
Polysci majors are used in governments, corporations, etc. to use the media (especially social media today) to shape public opinion. Admirable when used with integrity and honesty; despicable when used as we are witnessing with NWBO.
I would be curious as to big pharma advertising revenue stream for certain media (TV) - monied clients wield plenty of influence.
Quote:
“No AF postings today. Hmmm i guess he's just so busy he hasnt got the time to write his witty remarks"
Well, here’s something witty…..
The timing of NWBO’s decision to delist is quite intriguing when matched, date-wise, with AF’s departure post on this MB. It is curious, or humorous, that his “goodbye” to the board closely precedes NWBO’s “goodbye” to Nasdaq.
I attempted to locate that post but, alas, it has disappeared.
Quote
"Maybe you are right and my anger is misplaced. I know there are several factors, (hedge funds, buerocracies like FDA, etc). But I don't leave management off this list. "
Savage….
What I “hear” in your post is the financial strangulation caused by an unusual lengthy wait for meaningful news from management. It’s only human to blame people who possess information that could alleviate your anxiety or allow you an opportunity to make financial decisions. I understand!
Most of us are dealing with angst while we wait for NWBO’s good news; news to celebrate with one another and, most of all, share with victims of cancer and their families. I believe it’s coming.
“And hopefully Linda and Les can pull their F ing heads out of their asses.”
Savage39….Your last sentence seems incongruent with your overall post. I think your anger is misplaced. The relentless attack on this struggling, small biotech has been merciless rendering management to be silent. The lone avenue for putting forth NWBO’s efforts and accomplishments are in private meetings and trade conferences.
Having said that, my prayers and hopes are for the little one and her parents who are in hopes of a miraculous cure.
Indeed…In April 2016:
“The Parker Institute was created through a $250 million grant from The Parker Foundation, which is the largest single contribution ever made to the field of cancer immunotherapy. The UCLA center will receive initial funding of $10 million, with an additional $10 million investment over four years.”
Additional Merck connection:
“UCLA’s center will be led by Dr. Antoni Ribas, who developed Keytruda.”
UCLA NewsRoom
Interesting news article about Parker Institute. Note partnership with Bionetworks, a spinoff of Merck.
http://www.genengnews.com/gen-news-highlights/parker-institute-cri-partner-to-develop-cancer-immunotherapies/81253485
BRAVO! May the Force be with you.
Are you speaking of Ms. Linda Powers? CEO Northwest Biotherapeutics
“Ms. Powers is a Board member of M2GEN (an affiliate of Moffitt Cancer Center), the Trudeau Institute (a specialized research institute focused on immunology), the Chinese Biopharmaceutical Association, and the Rosalind Franklin Society. She was the Chair of the Maryland Stem Cell Research Commission for the first two years of the state’s stem cell funding program, and has served an additional four years on the Commission. Ms. Powers served for several years on a Steering Committee of the National Academy of Sciences, evaluating government research funding, and has been appointed to three Governors’ commissions created to determine how to build the respective states’ biotech and other high-tech industries. For more than six years, Ms. Powers taught an annual internal course at the National Institutes of Health for the bench scientists and technology transfer personnel on the development and commercialization of medical products.”
Oh, oh! Could that be Mr. Black knocking at the door?
Now you madam, are an authentic, investigative journalist! You put some people to shame!
See bottom of the form for signup
http://www.nwbio.com/contact-us/
Quote: "Just my 2 barrels worth"
2 barrels of what?
I receive the Moonshot Newsletter and have been casually following along with many MB posters. Although Dr. Soon-Shiong is worthy of great admiration in his field of work, I am curious as to his many companies in the health field. I believe he is also a major shareholder and on the BOD of Tribune Publishing Co. The list is impressive and, of course, many people of his stature are well connected. However, to wield power and influence over a federal initiative will always cause one to consider the opportunity to pick winners and losers. IMO needless to say.
http://www.nantworks.com
Thanks Flipper. I noted that Catapult (Precision Medicine) will also be present at Immunology World 2017. Their new facility in Stevenage (25 miles southwest of Sawston) will open in 2017. The Catapult centers are an economic ecosystem in the UK
https://ct.catapult.org.uk/how-we-work/our-facilities/manufacturing-centre-stevenage-uk
“The Catapult centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.”
https://catapult.org.uk
Ah yes, hence the new uptick pilot project
I think it's called positioning oneself in the industry
A small but interesting update: Northwest Biotherapeutics has just been listed as an Associate Sponsor at the Immunotherapy World/Cell & Gene Therapy World scheduled in Miami for January 17-20, 2017. Cognate BioServices has been listed for months as a Gold Sponsor but NWBO has just now been added.
http://www.immunotherapyforum.com/welcome
I concur with you in that our current administration aspires to leave a legacy and falling short in areas of the economy, homeland security, etc., the area of choice is health - my opinion, of course.
You may be interested in last week’s Moonshot2020 recent report delivered by VP Biden:
https://www.whitehouse.gov/the-press-office/2016/10/17/fact-sheet-vice-president-biden-delivers-cancer-moonshot-report
Oh snap! My favorite part of this drama was the mysterious appearance of AF at 6:45 am this morning.
I have no idea. Perhaps the “collaboration” stipulation among the funding grantees eliminated or lessened any monetary burden on them.
Jonsson Comprehensive CancerCenter was one of the six cancer research center recipients receiving funds from The Parker Foundation (Sean Parker.)
Collaboration among the recipients is an objective of the funding.
http://dailybruin.com/2016/04/13/ucla-to-establish-cancer-research-center-with-funds-from-250m-donation/
Also note the recent (August 2016) relationship with Asterias Biotherapeutics and Cognate
http://www.smartbrief.com/s/2016/08/asterias-enters-cancer-vaccine-manufacturing-deal-cognate
Back on line….In Palm Beach County and thankful Monsieur Matthew is gone. Great coordination and communication by officials. Took me awhile to catch up on posts - quality contributions as always.
Doc - Not aware of any other legislation addressing this same issue
You can track this bill in the US Congress - https://www.govtrack.us/congress/bills/114/s2720
If you Google Brokaw Act, you'll find plenty of content that supports this needed legislation.
Maverick - your quote:
“The FACTS as presented for those here who are blatantly oblivious and ignorant to the existent of Naked ILLEGAL SHORTING: “
S. 2720: Brokaw Act (U.S. Senate Bill)
Referred to committee back in March 2016 Consensus of opinion is that this bill is unlikely to ever get passed; however, it is an attempt by some legislators (Bill ’s sponsors) that legislation needs to be tightened to control these “groups” that do indeed exist
Duly noted, thanks
“An investment in knowledge always pays the best interest.”
? Benjamin Franklin
I believe the current CEO of KCG was formerly with UBS.
What amuses me is that the talking heads on the financial channels keep pointing out that there is so much capital on the sidelines and they muse over the reasons as to why potential investors are reluctant to be more active in the markets.
Because BMY has been mentioned frequently on this NWBO msg board in regard to partnerships, it may be of interest to some that BMY is taking part in Leerink Partners Immuno-Oncology Roundtabe Conference on 9.29.2016 and Fouad Namouni, SVP, Head of Oncology, will be accepting questions at 3:00 pm. There is a webcast
http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Bristol-Myers-Squibb-to-Take-Part-in-Leerink-Partners-Immuno-Oncology-Roundtable-Conference/default.aspx
“We are also investigating other immune system pathways in the treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO, and LAG-3. These pathways may lead to potential new treatment options – in combination or monotherapy – to help patients fight different types of cancers.
Our collaboration with academia, as well as small and large biotech companies, to research the potential Immuno-Oncology and non-Immuno-Oncology combinations, helps achieve our goal of providing new treatment options in clinical practice.”
Segment of Press Release from BMY September 20, 2016
http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-in-Advanced-Form-of-Bladder-Cancer/default.aspx